Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	XL147	3	72	flat	flat	HCC70 pilaralisib 0 3 72	8	2.478	Inf	1.03	-0.0199	0.0	1.03	0.01	-0.318	1.0	1.02	Inf	1.03	1.03	0.0	1.03	0.01	-0.331	1.0	1.02
HCC70	XL147	1	72	flat	flat	HCC70 pilaralisib 0 1 72	8	1.396	Inf	1.05	-0.0406	0.0	1.05	0.01	-0.285	1.0	1.03	Inf	1.04	1.03	0.0	1.04	0.01	-0.295	1.0	1.02
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	CAL-101	1	72	flat	flat	HCC1806 idelalisib 0 1 72	8	2.695	Inf	1.02	-0.0102	0.0	1.02	0.01	-0.593	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
Hs 578T	XL147	3		flat	flat	Hs578T pilaralisib 3	8	2.879	Inf	0.971	-0.00618	0.0	0.971	0.01	0.331	0.299	1.0	Inf	0.959	1.01	0.0	0.959	0.01	0.319	0.315	1.0
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
HCC38	AS605240	3	72	flat	flat	HCC38 AS-605240 0 3 72	8	1.343	Inf	0.958	-0.0162	0.0	0.958	0.01	-0.233	1.0	1.01	Inf	0.972	1.01	0.0	0.972	0.01	-0.235	1.0	1.01
HCC1806	CAL-101	3	72	flat	flat	HCC1806 idelalisib 0 3 72	8	3.147	Inf	1.02	-0.00869	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.587	1.0	1.02
Hs 578T	XL147	2		flat	flat	Hs578T pilaralisib 2	8	2.509	Inf	0.976	0.000255	0.0	0.976	0.01	0.435	0.181	0.997	Inf	0.97	1.0	0.0	0.97	0.01	0.432	0.183	0.996
BT-20	TGX221	1	72	flat	flat	BT20 TGX-221 0 1 72	8	1.988	Inf	1.02	-0.00357	0.0	1.02	0.01	-0.00762	1.0	1.0	Inf	1.02	1.0	0.0	1.02	0.01	-0.00881	1.0	1.0
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	AZD-6482	1	72	flat	flat	HCC1806 AZD6482 0 1 72	8	2.748	Inf	1.0	0.00141	0.0	1.0	0.01	-0.00621	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
HCC38	CAL-101	1	72	sigmoid	sigmoid	HCC38 idelalisib 0 1 72	8	1.723	Inf	0.92	0.00328	1.18	0.903	1.47	0.768	0.0125	NA	Inf	0.932	0.997	1.16	0.918	1.48	0.763	0.0133	NA
Hs 578T	XL147	1		flat	flat	Hs578T pilaralisib 1	8	2.013	Inf	0.967	0.00411	0.0	0.967	0.01	0.193	0.525	0.991	Inf	0.967	0.996	0.0	0.967	0.01	0.196	0.519	0.991
HCC70	KIN001-244	1	72	flat	flat	HCC70 KIN001-244 0 1 72	8	1.350	Inf	0.889	0.00722	0.0	0.889	0.01	0.616	0.0568	0.988	Inf	0.926	0.995	0.0	0.926	0.01	0.612	0.0584	0.992
BT-549	KIN001-244	2	72	sigmoid	sigmoid	BT549 KIN001-244 0 2 72	8	1.920	Inf	0.882	0.00561	2.72	0.793	1.67	0.73	0.0197	NA	Inf	0.89	0.995	2.6	0.813	1.68	0.718	0.0225	NA
HCC1806	PI103	3	72	sigmoid	sigmoid	HCC1806 PI-103 0 3 72	8	3.126	Inf	0.91	0.00588	1.72	0.873	1.43	0.782	0.0103	NA	Inf	0.866	0.992	1.61	0.817	1.44	0.762	0.0134	NA

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)